Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending April 5, 2015
AML Care: Good News from SEER database, Change in early death, median survivals
ACS Guidelines: Caring For Prostate Cancer Survivors , Recommendations for treating after-effects of cancer
Predicting Adenomas Prior to Colonoscopy, New model developed for estimating colon cancer risk
Is There a Link Between Breast and Prostate Cancers?, Breast cancer risk exacerbated with family history of both
Must reads for theWeek ending March 29, 2015
Observation or Radiotherapy After Breast Conserving Surgery, Which has a lower local failure rate?
A More Accurate Predictor of Breast Cancer, New assessment tool for women with benign breast disease
Improved Prognostic Performance Model for MRCC , IMDC compared with MSKCC model for renal cell carcinoma
Unituxin Approved for High-Risk Neuroblastoma, GD2-binder is first approved for high-risk condition
Must reads for theWeek ending March 22, 2015
CDC: Cancer Survival Rates On The Rise, Report highlights incidence and mortality rates by type of cancer
Is Androgen-Deprivation Therapy Monotherapy Enough? , Three-cohort study compares ADT with and without radiotherapy
Increase in Adjuvant Chemotherapy Use in Stage I Breast Cancer, A closer look at treatment rates from 2000 to 2009
Postoperative Radio Therapy Improves Survival in NSCLC, A review of patients from the National Cancer Data Base
FDA Approves First Biosimilar Product Filgrastim-sndz, Injection available in two pre-filled doses
Must reads for theWeek ending March 15, 2015
2 Steps to Ensure Melanomas Aren’t Missed, How effective is the dermoscopy algorithm?
Is Colon Resection or CME Surgery More Successful?, Disease-free survival rates in patients with colon adenocarcinoma
Preventing Colorectal Cancer Deaths, More screening recommended
Depigmentation in Melanoma Following Immunotherapy, Vitiligo-like reaction in patients linked to survival
Opdivo Granted Accelerated FDA Approval, PD-1 blocking antibody to treat melanoma, NSCL cancer
Must reads for theWeek ending March 8, 2015
FDA Approves Palbociclib for Postmenopausal Breast Cancer, Indicated for ER-positive, HER2-negative patients
FDA Approves New Treatment for Thyroid Cancer, Lenvatinib treats iodine-refractory differentiated disease
FDA Approves Panobinostat for Multiple Myeloma, Accelerated approval due to progression-free survival
Could Allergies Protect Against non-Hodgkin Lymphoma?, Results from the Agricultural Health Study
Combination Treatment Extends Survival in HER2 Patients, Results of the CLEOPATRA study